Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer

Journal of Nuclear Medicine

Volumn 50, Issue 12, 2009, Pages 1948-1953

  Lohith, Talakad Goolaiah ^a   Kudo, Takashi ^a   Demura, Yoshiki ^a   Umeda, Yukihiro ^a   Kiyono, Yasushi ^a   Fujibayashi, Yasuhisa ^a   Okazawa, Hidehiko ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

18F FDG; 62Cu ATSM; Hypoxia; Lung cancer; PET

Indexed keywords

DIACETYLBIS(N 4 METHYLTHIOSEMICARBOZONE) CU 62; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG; COPPER; COPPER (II) DIACETYL DI(N(4) METHYLTHIOSEMICARBAZONE); COPPER (II) DIACETYL-DI(N(4)-METHYLTHIOSEMICARBAZONE); DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND; THIOSEMICARBAZONE DERIVATIVE;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DISTRIBUTION; DRUG UPTAKE; ENERGY METABOLISM; FEMALE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMAGE RECONSTRUCTION; INFORMATION PROCESSING; LUNG ADENOCARCINOMA; LUNG LESION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGISTRATION; WHOLE BODY PET; ADENOCARCINOMA; CHEMISTRY; LUNG TUMOR; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TRANSPORT AT THE CELLULAR LEVEL;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; COPPER RADIOISOTOPES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; REGRESSION ANALYSIS; THIOSEMICARBAZONES;

EID: 73349100660     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.069021     Document Type: Article

References (32)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9:539-549.
2. Brown JM. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 1999;59:5863-5870.
3. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003;195:1-16.
4. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699-757.
5. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507-1514.
6. 2 availability on human cancer. Nat Rev Cancer. 2008;8:967-975.
7. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer. 2008;8:705-713.
8. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S.
9. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
10. Lewis JS, Herrero P, Sharp TL, et al. Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)- methylthiosemicarbazone). J Nucl Med. 2002;43:1557-1569.
11. Fujibayashi Y, Cutler CS, Anderson CJ, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26:117-121.
12. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
13. Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001;42:655-661.
14. 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med. 2000;14:323-328.
15. 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
16. 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844-850.
17. Bollschweiler E, Metzger R, Drebber U, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231-238.
18. Ishikawa H, Nakayama Y, Kitamoto Y, et al. Effect of histologic type on recurrence pattern in radiation therapy for medically inoperable patients with stage I non-small-cell lung cancer. Lung. 2006;184:347-353.
19. Vesselle H, Salskov A, Turcotte E, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3:971-978.
20. 62Cu-PTSM. Int J Rad Appl Instrum B. 1992;19:39-44.
21. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE. Performance characteristics of a whole body PET scanner. J Nucl Med. 1994;35:1398-1406.
22. Kamibayashi T, Tsuchida T, Demura Y, et al. Reproducibility of semiquantitative parameters in FDG-PET using two different PET scanners: influence of attenuation correction method and examination interval. Mol Imaging Biol. 2008;10:162-166.
23. 18F-FDG PET. J Nucl Med. 2006; 47:1921-1926.
24. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.
25. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Copper-62 ATSM as a hypoxic tissue tracer in myocardial ischemia. Ann Nucl Med. 2001;15:293-296.
26. Obata A, Yoshimi E, Waki A, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4- methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001; 15:499-504.
27. Holland JP, Barnard PJ, Collison D, et al. Spectroelectrochemical and computational studies on the mechanism of hypoxia selectivity of copper radiopharmaceuticals. Chem Eur J. 2008;14:5890-5907.
28. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009; 53:193-200.
29. 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008;35:713-720.
30. 64Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529-534.
31. Oh M, Tanaka T, Kobayashi M, et al. Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol. 2009;36:419-426.
32. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol. 2006;33:743-750.